Cargando…

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer

We sought to characterise whether dexamethasone (DEX) may enhance tumour response to docetaxel in in vitro and in vivo models of metastatic prostate cancer (CaP). In vitro experiments conducted on PC3 and human bone marrow endothelial cells (hBMECs) determined that administration of DEX (10 nM) redu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilson, C, Scullin, P, Worthington, J, Seaton, A, Maxwell, P, O'Rourke, D, Johnston, P G, McKeown, S R, Wilson, R H, O'Sullivan, J M, Waugh, D J J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607236/ https://www.ncbi.nlm.nih.gov/pubmed/19050703 http://dx.doi.org/10.1038/sj.bjc.6604804

Ejemplares similares

Inhibition of constitutive and cxc-chemokine-induced NF-κB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells
por: Seaton, A, et al.
Publicado: (2009)

The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue
por: Oladipo, O, et al.
Publicado: (2011)

Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance
por: Browne, G, et al.
Publicado: (2012)

Gene expression profile and response to trastuzumab–docetaxel-based treatment in breast carcinoma
por: Végran, F, et al.
Publicado: (2009)

Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study
por: Mukherjee, A, et al.
Publicado: (2005)

Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer
por: Mukherjee, R, et al.
Publicado: (2011)

Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients
por: Fajac, A, et al.
Publicado: (2010)

NFκB signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression
por: McCall, P, et al.
Publicado: (2012)

Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo
por: Gassler, N, et al.
Publicado: (2005)

A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol
por: Shamash, J, et al.
Publicado: (2011)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2014)

Antiangiogenic Cancer Therapy
por: Maxwell, P H, et al.
Publicado: (2009)

Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer
por: Armstrong, K, et al.
Publicado: (2011)

Tumour microenvironment of both early- and late-stage colorectal cancer is equally immunosuppressive
por: O'Toole, A, et al.
Publicado: (2014)

Impact of p16 status on pro- and anti-angiogenesis factors in head and neck cancers
por: Baruah, P, et al.
Publicado: (2015)

Expression of a protease-resistant insulin-like growth factor-binding protein-4 inhibits tumour growth in a murine model of breast cancer
por: Ryan, A J, et al.
Publicado: (2009)

Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients
por: Hurst, N G, et al.
Publicado: (2007)

Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro
por: Prencipe, M, et al.
Publicado: (2009)

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy
por: Jürgensmeier, J M, et al.
Publicado: (2013)

Expression of CC chemokine receptor 7 in tonsillar cancer predicts cervical nodal metastasis, systemic relapse and survival
por: Pitkin, L, et al.
Publicado: (2007)

Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer
por: Papadaki, C, et al.
Publicado: (2011)

Molecular profiling of cervical cancer progression
por: Hagemann, T, et al.
Publicado: (2007)

Curcumin induces apoptosis-independent death in oesophageal cancer cells
por: O'Sullivan-Coyne, G, et al.
Publicado: (2009)

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005)

<i>CYLD</i> GeneticTesting for Brooke-Spiegler Syndrome, Familial Cylindromatosis and Multiple Familial Trichoepitheliomas
por: Dubois, Anna, et al.
Publicado: (2015)

A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei
por: Bibi, R, et al.
Publicado: (2006)

Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial
por: Noguchi, Masanori, et al.
Publicado: (2020)

Complexities and benefits of adopting next-generation sequencing-based tuberculosis diagnostics: a qualitative study among stakeholders in low and high-income countries
por: Grandjean Lapierre, Simon, et al.
Publicado: (2023)

The Rate of Magnetic Resonance Imaging in Patients With Spinal Cord Stimulation
por: Desai, Mehul J., et al.
Publicado: (2015)

The BH3 mimetic HA14-1 enhances 5-fluorouracil-induced autophagy and type II cell death in oesophageal cancer cells
por: Nyhan, M J, et al.
Publicado: (2012)

Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer
por: Mout, Lisanne, et al.
Publicado: (2020)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance
por: Palmieri, C, et al.
Publicado: (2013)

Prospective analysis of the accuracy of diagnosis of carpal tunnel syndrome using a web-based questionnaire
por: Bland, Jeremy D P, et al.
Publicado: (2014)

Apoptosome-dependent caspase activation proteins as prognostic markers in Stage II and III colorectal cancer
por: Hector, S, et al.
Publicado: (2012)

Prospective Register Of patients undergoing repeated OFfice and Ambulatory Blood Pressure Monitoring (PROOF-ABPM): protocol for an observational cohort study
por: Sheppard, James P, et al.
Publicado: (2016)

Common evidence gaps in point-of-care diagnostic test evaluation: a review of horizon scan reports
por: Verbakel, Jan Y, et al.
Publicado: (2017)

Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis
por: Zhong, Lixian, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5hup3avbhh3rlbbscpnhc09fqu